In the US, another potential treatment option could be on the horizon. According to a recent report from FiercePharma:
In coming years, the kidney cancer drug pipeline will continue to have a flow of new drugs entering the market. It will be crucial to keep a close eye on the market access in this class.
"Bristol-Myers Squibb could have yet another approval for its Opdivo-plus-Yervoy combo on the way. The FDA has started a priority review on the two-drug combo as a treatment for kidney cancer, based on data released just three months ago.The combination regimen, which pairs Bristol's PD-1 immunotherapy Opdivo with its CTLA4 drug Yervoy, is up for an approval for intermediate- and poor-risk patients with advanced renal cell carcinoma, and the FDA is due to decide next April."
Subscribe to the MMIT blog for more pharma, provider, and payer perspectives on key topics that affect the healthcare network.